Rubicon Research AcetaZOLAMIDE Tablets Recall: Discoloration Hazard
Rubicon Research recalls 125mg AcetaZOLAMIDE tablets due to discoloration. This may affect appearance but does not indicate safety issues. No action needed per official notice.
Lower-risk recall
Discoloration
Contact the company
What happened, in plain English
Rubicon Research is recalling 125mg AcetaZOLAMIDE tablets that may have discoloration. This issue does not pose a safety risk and requires no action from consumers. Read more at govinfonow.com/recall/32552-rubicon-research-acetazolamide-tablets-recall-discoloration-hazard.
Source Summary by GovInfoNow · govinfonow.com/recall/32552-rubicon-research-acetazolamide-tablets-recall-discoloration-hazard · Updated August 17, 2026 · FDA enforcement record: FDA #D-0659-2024
Cite this page
“Rubicon Research AcetaZOLAMIDE Tablets Recall: Discoloration Hazard.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32552-rubicon-research-acetazolamide-tablets-recall-discoloration-hazard. Based on FDA recall #D-0659-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0659-2024%22&limit=1).
Why it’s dangerous
Discoloration in the tablets is a visual change that does not indicate a safety hazard. The recall is for cosmetic reasons only, as the tablets remain safe for use.
Who’s affected
Prescription patients who received the recalled 125mg AcetaZOLAMIDE tablets from Rubicon Research. No specific groups are at higher risk.
How to tell if you have this one
Check for the product name 'AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled' with NDC 72888-047-01 and lot number 30575HF1. These were distributed by Advagen Pharma Limited in the US.
- Brand
Rubicon Research- Category
Drug
What to do — step by step
Check Product Details
Review the product label for NDC 72888-047-01 and lot number 30575HF1 to confirm if it's affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 32 days after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0659-2024 (August 24, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0659-2024 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.